Japanese Government Looks To Increase Funding For Cancer Research
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Aggregate fiscal 2009 budget requests for cancer research, treatment and other administrative measures of the Japanese government would grow 10.8 percent from fiscal 2008 to ¥60.5 billion ($672 million), according to the budget requests of the Ministry of Health, Labor and Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; and the Ministry of Economy, Trade and Industry
You may also be interested in...
Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition
TOKYO - Eisai registered swift benefits from its acquisition of MGI Pharma with oncology revenues accounting for 10 percent of its global sales, Eisai CEO Haruo Naito told an Oct. 31 earnings conference
Japan’s MHLW Seeks 21% Budget Increase For Innovative Drugs
TOKYO - Japan's Ministry of Health Labor and Welfare is seeking a hefty 21 percent increase for developing innovative drugs and medical devices, according to its fiscal 2009 budget request submitted in late August
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda's acquisition of Millennium for $8.8 billion will extend the Japanese drug maker's presence in oncology and help stem the loss of revenues as key drugs go generic. Takeda announced plans to acquire the Cambridge, Mass.-based biotech April 10 for $25 per share, a 53 percent premium over the April 9 closing price